From leasing to new construction, pharmaceutical and life sciences firms remained a leading force in New Jersey’s commercial real estate market through the first three quarters of 2022.
Despite years of consolidation by Big Pharma, New Jersey is one of a handful of markets that stand to gain from a promising growth trajectory for the U.S. life sciences sector.
By Joshua Burd JLL has bolstered its life sciences practice with the addition of John Cunningham, a broker with more than 30 years of experience in the state’s commercial real estate sector. The firm announced Tuesday that Cunningham has been…
A wave of acquisition and divestment activity is reshaping the life sciences industry — and its real estate needs — resulting in demands for new office space and a surplus of lab inventory. A new report reminds us that New Jersey is seeing many of those changes firsthand.
A panel discussion hosted by NAIOP New Jersey focused on why and how “next-generation” companies are able to grow in the Garden State — and how the commercial real estate industry can support them in their growth.
